 |
[Alpha Biz=(Chicago) Reporter Kim Jisun] Samsung BioLogics surpassed KRW 2 trillion in accumulated orders for consignment production contracts (CMO) for the first time.
Following Pfizer, a global pharmaceutical company, it signed a large-scale drug consignment production (CMO) contract with Novartis. It broke the record of about 1.9 trillion won in 2020, when it achieved the highest order amount ever, in about six months. Adding to its performance in the second half of the year, the cumulative order amount of Samsung BioLogics is expected to increase this year.
Samsung BioLogics announced on the 10th that it has signed an CMO contract worth 390 million dollars (about 511.1 billion won) with Novartis, the world's top five pharmaceutical companies. Less than a week after announcing a $887 million CMO contract with Pfizer on the 4th, a large-scale contract performance was added.
As a result, Samsung Biologics' cumulative order amount this year reached a record high of 2.3387 trillion won based on the disclosure. This month, the amount of contracts with Pfizer and Novartis alone amounted to more than 1.7 trillion won, which is similar to last year's total order amount of 1.7835 trillion won. Samsung BioLogics surpassed $ 10 billion (about 13 trillion won) in accumulated orders last month. So far, 13 of the world's top 20 big pharma companies have been secured as customers.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
